John Schmid Biography and Net Worth

Director of Design Therapeutics

John Schmid serves as a member of the boards of directors of AnaptysBio, Inc. (ANAB), Helix Acquisition Corp II (HLXB), and Xeris Pharmaceuticals (XERS). In addition, Mr. Schmid serves as chairman of the board of directors of Speak, Inc., a speakers bureau, which he helped found in 1989. Mr. Schmid also served as a member of the boards of directors of Poseida Therapeutics Inc., Neos Therapeutics, Blacksmith Medicines (formerly known as Forge Therapeutics, Inc.) and Helix Acquisition Corporation. Previously, Mr. Schmid served as chief financial officer of Auspex Pharmaceuticals, Inc. until its sale to Teva Pharmaceutical Industries Ltd. Prior to that, Mr. Schmid co-founded Trius Therapeutics where he served as the chief financial officer until its merger with Cubist Pharmaceuticals, Inc. Prior to Trius Therapeutics, Mr. Schmid served as the chief financial officer of GeneFormatics, Inc. and Endonetics Inc. Mr. Schmid received a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.

What is John P. Schmid's net worth?: The estimated net worth of John P. Schmid is at least $203.13 thousand as of August 9th, 2024. Mr. Schmid owns 20,685 shares of Design Therapeutics stock worth more than $203,127 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Schmid may own. Learn More about John P. Schmid's net worth.
How do I contact John P. Schmid?: The corporate mailing address for Mr. Schmid and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on John P. Schmid's contact information.
Has John P. Schmid been buying or selling shares of Design Therapeutics?: John P. Schmid has not been actively trading shares of Design Therapeutics within the last three months. Most recently, on Monday, March 25th, John P. Schmid bought 17,809 shares of Design Therapeutics stock. The stock was acquired at an average cost of $3.74 per share, with a total value of $66,605.66. Following the completion of the transaction, the director now directly owns 26,965 shares of the company's stock, valued at $100,849.10. Learn More on John P. Schmid's trading history.
Who are Design Therapeutics' active insiders?: Design Therapeutics' insider roster includes Rodney Lappe (Director), Deepa Prasad (Director), John Schmid (Director), and Arsani William (Director). Learn More on Design Therapeutics' active insiders.
Are insiders buying or selling shares of Design Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 3,806 shares worth more than $23,863.62. The most recent insider tranaction occured on December, 18th when Director Deepa Prasad sold 3,806 shares worth more than $23,863.62. Insiders at Design Therapeutics own 23.5% of the company. Learn More about insider trades at Design Therapeutics.
Information on this page was last updated on 12/18/2024.

John P. Schmid Insider Trading History at Design Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/25/2024	Buy	17,809	$3.74	$66,605.66	26,965
3/22/2024	Buy	9,156	$3.62	$33,144.72	9,156

John P. Schmid Buying and Selling Activity at Design Therapeutics

Design Therapeutics Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $9.82

$9.33

$10.02

50 Day Range

MA: $7.21

$5.53

$9.82

2 Week Range

Now: $9.82

$2.60

$10.02

Volume

320,153 shs

Average Volume

514,527 shs

Market Capitalization

$559.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63